Product Description: Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC)[1][2].
Applications: Cancer-programmed cell death
Formula: C21H27ClO5
References: [1]Myung JK, et, al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013 Jul;123(7):2948-60./[2]Yang YC, et, al. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016 Sep 1;22(17):4466-77.
CAS Number: 1203490-23-6
Molecular Weight: 394.89
Compound Purity: 99.78
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Androgen Receptor
Deutsch
English
